佩格瓦利酶治疗使成年人患有基尿症的血液神经递质代谢物正常化
Monika A Sigg1, Christopher Wilson2, Gillian E Clague1
1BioMarin Pharmaceutical Inc., Novato, CA, USA.
Molecular genetics and metabolism
|October 10, 2024
概括
基尿症 (PKU) 患者用佩格瓦里酶治疗使神经递质代谢物水平正常化. 这种酶疗法改善了血液代谢物水平,与PKU患者的氨酸 (Phe) 降低相关.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
背景情况:
- 基尿症 (PKU) 是由于氨酸氧化酶 (PAH) 活性不足造成的,导致有毒氨酸 (Phe) 积累.
- 异常的Phe和氨酸水平会破坏大脑神经递质的合成,可能导致认知和精神问题.
- 血液中神经递质代谢物 (NTM) 可能表明大脑中的NTM水平.
研究的目的:
- 为了评估接受佩格瓦里酶治疗的PKU患者血液NTM和血液Phe之间的关系.
- 为了评估24个月内佩格瓦里亚酶治疗期间血液NTM的变化.
主要方法:
- 在109名用pegvaliase治疗的PKU患者中分析了血液NTM (HVA,MOPEG,5HIAA,PAG) 和Phe水平 (PRISM-1和PRISM-2试验).
- 在91名参与者的基线和12个月和24个月的随访期间,NTM水平的比较.
- 在NTM和Phe水平之间的相关性分析.
主要成果:
- 在基线,与对照组相比,PKU患者的NTM概况发生了变化 (较低的HVA,MOPEG,5HIAA;较高的PAG).
- PAG水平与Phe正相关,而HVA,MOPEG和5HIAA与Phe负相关.
- 佩格瓦利治疗改善了NTM水平,使其正常化,因为Phe水平在24个月后下降到360μmol/L以下.
结论:
- 血液中的NTM水平与PKU中的Phe水平密切相关.
- 佩格瓦里酶疗法有效地改善了PKU患者的血液NTM概况.
- 作为监测PKU治疗疗效的生物标志物,NTM显得有前途.
相关概念视频
Inborn Errors of Metabolism
140
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
140
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
96
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
96
Parkinson's Disease: Treatment
231
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
231
Overview of Protein Metabolism
788
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
788
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
263
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
263


